8-KShareholder MattersCorporate ChangesExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Bylaw Amendment (Apr 26, 2019)

Filed April 26, 2019For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed this 8-K on April 26, 2019, primarily to report on the outcomes of its 2019 Annual Meeting of Stockholders held on April 25, 2019. Key corporate governance changes were approved by stockholders, including amendments to the Company's Certificate of Incorporation and Bylaws. These changes empower stockholders to call special meetings under certain conditions and significantly increase the authorized number of common shares. The company also re-elected its Class III directors, approved amendments to its 2018 Stock Incentive Plan, ratified the appointment of PricewaterhouseCoopers LLP as its independent auditor, and approved executive compensation in a non-binding advisory vote. These actions are significant for shareholder rights and future capital raising flexibility.

Key Highlights

  • 1Stockholder approval was obtained to allow holders of at least a majority of common stock to call special meetings, enhancing shareholder governance.
  • 2The number of authorized common stock shares was doubled from 125,000,000 to 250,000,000, providing significant flexibility for future fundraising or strategic initiatives.
  • 3Four Class III directors were re-elected to serve until the 2022 annual meeting, indicating continued confidence in board leadership.
  • 4An amendment to the Company's 2018 Stock Incentive Plan was approved, which is relevant for employee compensation and retention strategies.
  • 5The appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2019 was ratified, confirming auditor continuity.
  • 6A non-binding advisory vote approved the compensation of named executive officers, reflecting shareholder sentiment on executive pay.
  • 7The filing formally integrates all amendments to the Company's Restated Certificate of Incorporation.

Frequently Asked Questions

The most significant corporate governance change is the amendment allowing stockholders, holding at least a majority of the common stock, to call special meetings. This enhances shareholder power in initiating important corporate actions outside of regular annual meetings, subject to specific procedural requirements.

Doubling the authorized common stock from 125 million to 250 million shares provides Alnylam with substantial flexibility for future corporate activities. This could include raising capital through stock offerings, facilitating acquisitions, implementing employee stock plans, or other strategic transactions without needing immediate further shareholder approval for such increases.

Four Class III directors (Margaret A. Hamburg, M.D., Steven M. Paul, M.D., Colleen F. Reitan, and Amy W. Schulman) were re-elected to serve until the 2022 annual meeting of stockholders. The voting results showed strong support for their re-election.

The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2019. This ratification indicates shareholder confidence in the audit firm.